Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Schizophrenia

  Free Subscription


Articles published in Psychol Med

Retrieve available abstracts of 223 articles:
HTML format
Text format



Single Articles


    February 2020
  1. COLIZZI M, Ruggeri M, Lasalvia A
    Should we be concerned about stigma and discrimination in people at risk for psychosis? A systematic review.
    Psychol Med. 2020 Feb 17:1-22. doi: 10.1017/S0033291720000148.
    PubMed     Text format     Abstract available


  2. WEARNE TA, McDonald S
    Social cognition v. emotional intelligence in first-episode psychosis: are they the same?
    Psychol Med. 2020 Feb 10:1-2. doi: 10.1017/S0033291720000185.
    PubMed     Text format    


  3. OSBORNE KJ, Damme KSF, Gupta T, Dean DJ, et al
    Timing dysfunction and cerebellar resting state functional connectivity abnormalities in youth at clinical high-risk for psychosis.
    Psychol Med. 2020 Feb 3:1-10. doi: 10.1017/S0033291719004161.
    PubMed     Text format     Abstract available


    January 2020
  4. O'NEILL A, Wilson R, Blest-Hopley G, Annibale L, et al
    Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
    Psychol Med. 2020 Jan 29:1-11. doi: 10.1017/S0033291719003519.
    PubMed     Text format     Abstract available


  5. VAN LEEUWEN JMC, Vinkers CH, Vink M, Kahn RS, et al
    Disrupted upregulation of salience network connectivity during acute stress in siblings of schizophrenia patients.
    Psychol Med. 2020 Jan 16:1-11. doi: 10.1017/S0033291719004033.
    PubMed     Text format     Abstract available


  6. GUO JY, Lesh TA, Niendam TA, Ragland JD, et al
    Brain free water alterations in first-episode psychosis: a longitudinal analysis of diagnosis, course of illness, and medication effects.
    Psychol Med. 2020 Jan 8:1-10. doi: 10.1017/S0033291719003969.
    PubMed     Text format     Abstract available


    December 2019
  7. PINKHAM AE, Sasson NJ
    The benefit of directly comparing autism and schizophrenia, revisited.
    Psychol Med. 2019 Dec 20:1-3. doi: 10.1017/S0033291719003635.
    PubMed     Text format    


  8. POKORNY VJ, Lano TJ, Schallmo MP, Olman CA, et al
    Reduced influence of perceptual context in schizophrenia: behavioral and neurophysiological evidence.
    Psychol Med. 2019 Dec 20:1-9. doi: 10.1017/S0033291719003751.
    PubMed     Text format     Abstract available


  9. NKIRE N, Scully PJ, Browne DJ, Baldwin PA, et al
    Systematic epidemiological and clinical comparisons across all 12 DSM-IV psychotic diagnoses in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS).
    Psychol Med. 2019 Dec 20:1-10. doi: 10.1017/S0033291719003520.
    PubMed     Text format     Abstract available


  10. MORITZ S, Gaweda L, Heinz A, Gallinat J, et al
    Early detection. A defense of our statement that we should not catastrophize a future we cannot reliably predict nor change. A plea for a faster transition of traditional 'early intervention' programs for psychosis into new treatment models.
    Psychol Med. 2019 Dec 20:1-4. doi: 10.1017/S0033291719003477.
    PubMed     Text format    


  11. VIEIRA S, Gong Q, Scarpazza C, Lui S, et al
    Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis.
    Psychol Med. 2019 Dec 20:1-11. doi: 10.1017/S0033291719003568.
    PubMed     Text format     Abstract available


  12. COHEN A, Morgan C
    Estimating the incidence of psychosis in diverse settings.
    Psychol Med. 2019 Dec 17:1-2. doi: 10.1017/S0033291719003702.
    PubMed     Text format    


  13. HERBENER ES, Harrow M
    Course and symptom and functional correlates of passivity symptoms in schizophrenia: an 18-year multi-follow-up longitudinal study.
    Psychol Med. 2019 Dec 16:1-8. doi: 10.1017/S0033291719003428.
    PubMed     Text format     Abstract available


  14. ZHANG T, Xu L, Li H, Woodberry KA, et al
    Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: findings from ShangHai At Risk for Psychosis (SHARP) program.
    Psychol Med. 2019 Dec 16:1-8. doi: 10.1017/S003329171900360.
    PubMed     Text format     Abstract available


  15. HJORTHOJ C, Larsen MO, Starzer MSK, Nordentoft M, et al
    Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016.
    Psychol Med. 2019 Dec 16:1-6. doi: 10.1017/S0033291719003532.
    PubMed     Text format     Abstract available


  16. LIU Y, Mendonca M, Johnson S, O'Reilly H, et al
    Testing the neurodevelopmental, trauma and developmental risk factor models of psychosis using a naturalistic experiment.
    Psychol Med. 2019 Dec 9:1-10. doi: 10.1017/S0033291719003349.
    PubMed     Text format     Abstract available


  17. HJORTHOJ C, Uddin MJ, Wimberley T, Dalsgaard S, et al
    No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder.
    Psychol Med. 2019 Dec 9:1-6. doi: 10.1017/S0033291719003362.
    PubMed     Text format     Abstract available


    November 2019
  18. RABALLO A, Poletti M
    Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?
    Psychol Med. 2019 Nov 29:1-4. doi: 10.1017/S0033291719003337.
    PubMed     Text format     Abstract available


  19. CRESPI B
    How is quantification of social deficits useful for studying autism and schizophrenia?
    Psychol Med. 2019 Nov 22:1-3. doi: 10.1017/S0033291719003180.
    PubMed     Text format    


  20. ODUOLA S, Das-Munshi J, Bourque F, Gayer-Anderson C, et al
    Change in incidence rates for psychosis in different ethnic groups in south London: findings from the Clinical Record Interactive Search-First Episode Psychosis (CRIS-FEP) study.
    Psychol Med. 2019 Nov 19:1-10. doi: 10.1017/S0033291719003234.
    PubMed     Text format     Abstract available


  21. AYESA-ARRIOLA R, Ortiz-Garcia de la Foz V, Martinez-Garcia O, Setien-Suero E, et al
    Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort.
    Psychol Med. 2019 Nov 18:1-14. doi: 10.1017/S0033291719003179.
    PubMed     Text format     Abstract available


  22. WOOTTON RE, Richmond RC, Stuijfzand BG, Lawn RB, et al
    Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study.
    Psychol Med. 2019 Nov 6:1-9. doi: 10.1017/S0033291719002678.
    PubMed     Text format     Abstract available


  23. MARTIN-SUBERO M, Fuentes-Claramonte P, Salgado-Pineda P, Salavert J, et al
    Autobiographical memory and default mode network function in schizophrenia: an fMRI study.
    Psychol Med. 2019 Nov 4:1-8. doi: 10.1017/S0033291719003052.
    PubMed     Text format     Abstract available


    October 2019
  24. BRUCATO G, First MB, Dishy GA, Samuel SS, et al
    Recency and intensification of positive symptoms enhance prediction of conversion to syndromal psychosis in clinical high-risk patients.
    Psychol Med. 2019 Oct 29:1-9. doi: 10.1017/S0033291719003040.
    PubMed     Text format     Abstract available


  25. GONZALEZ-ORTEGA I, Gonzalez-Pinto A, Alberich S, Echeburua E, et al
    Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis.
    Psychol Med. 2019 Oct 22:1-9. doi: 10.1017/S0033291719002794.
    PubMed     Text format     Abstract available


  26. SIAFIS S, Deste G, Ceraso A, Mussoni C, et al
    Antipsychotic drugs v. barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis.
    Psychol Med. 2019 Oct 18:1-12. doi: 10.1017/S003329171900285.
    PubMed     Text format     Abstract available


  27. D'SOUZA DC, Ganesh S, Cortes-Briones J, Campbell MH, et al
    Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure.
    Psychol Med. 2019 Oct 16:1-8. doi: 10.1017/S0033291719002721.
    PubMed     Text format     Abstract available


  28. WONG TY, Radua J, Pomarol-Clotet E, Salvador R, et al
    An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium.
    Psychol Med. 2019 Oct 16:1-12. doi: 10.1017/S0033291719002149.
    PubMed     Text format     Abstract available


  29. CHANG WC, Westbrook A, Strauss GP, Chu AOK, et al
    Abnormal cognitive effort allocation and its association with amotivation in first-episode psychosis.
    Psychol Med. 2019 Oct 2:1-11. doi: 10.1017/S0033291719002769.
    PubMed     Text format     Abstract available


  30. PINKHAM AE, Morrison KE, Penn DL, Harvey PD, et al
    Comprehensive comparison of social cognitive performance in autism spectrum disorder and schizophrenia.
    Psychol Med. 2019 Oct 2:1-9. doi: 10.1017/S0033291719002708.
    PubMed     Text format     Abstract available


    September 2019
  31. PEREZ J, Jones PB
    Breaking the web: life beyond the at-risk mental state for psychosis.
    Psychol Med. 2019 Sep 30:1-6. doi: 10.1017/S0033291719002605.
    PubMed     Text format     Abstract available


  32. VASSOS E, Sham P, Kempton M, Trotta A, et al
    The Maudsley environmental risk score for psychosis.
    Psychol Med. 2019 Sep 19:1-8. doi: 10.1017/S0033291719002319.
    PubMed     Text format     Abstract available


  33. QUATTRONE D, Richards A, Reininghaus U, Vassos E, et al
    Letter to the editor: Is polygenic risk for Parkinson's disease associated with less risk of first episode psychosis?
    Psychol Med. 2019 Sep 19:1-4. doi: 10.1017/S0033291719002435.
    PubMed     Text format    


  34. EDWARDS CJ, Garety P, Hardy A
    The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis.
    Psychol Med. 2019 Sep 18:1-13. doi: 10.1017/S0033291719002381.
    PubMed     Text format     Abstract available


  35. HERNIMAN SE, Allott K, Phillips LJ, Wood SJ, et al
    Depressive psychopathology in first-episode schizophrenia spectrum disorders: a systematic review, meta-analysis and meta-regression.
    Psychol Med. 2019 Sep 16:1-12. doi: 10.1017/S0033291719002344.
    PubMed     Text format     Abstract available


  36. BOJESEN KB, Ebdrup BH, Jessen K, Sigvard A, et al
    Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naive patients with psychosis.
    Psychol Med. 2019 Sep 16:1-12. doi: 10.1017/S0033291719002277.
    PubMed     Text format     Abstract available


  37. GUO JY, Niendam TA, Auther AM, Carrion RE, et al
    Predicting psychosis risk using a specific measure of cognitive control: a 12-month longitudinal study.
    Psychol Med. 2019 Sep 11:1-10. doi: 10.1017/S0033291719002332.
    PubMed     Text format     Abstract available


  38. DWYER K, David AS, McCarthy R, McKenna P, et al
    Linguistic alignment and theory of mind impairments in schizophrenia patients' dialogic interactions.
    Psychol Med. 2019 Sep 10:1-9. doi: 10.1017/S0033291719002289.
    PubMed     Text format     Abstract available


    August 2019
  39. WAGGERSHAUSER M, Steinert T
    Breakthrough psychosis under antipsychotic maintenance treatment and social stress.
    Psychol Med. 2019 Aug 29:1-2. doi: 10.1017/S003329171900206.
    PubMed     Text format    


  40. SMART SE, Kepinska AP, Murray RM, MacCabe JH, et al
    Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies.
    Psychol Med. 2019 Aug 29:1-10. doi: 10.1017/S0033291719002083.
    PubMed     Text format     Abstract available


  41. WORTINGER LA, Engen K, Barth C, Lonning V, et al
    Obstetric complications and intelligence in patients on the schizophrenia-bipolar spectrum and healthy participants.
    Psychol Med. 2019 Aug 28:1-9. doi: 10.1017/S0033291719002046.
    PubMed     Text format     Abstract available


  42. MAKOWSKI C, Lewis JD, Lepage C, Malla AK, et al
    Intersection of verbal memory and expressivity on cortical contrast and thickness in first episode psychosis.
    Psychol Med. 2019 Aug 28:1-14. doi: 10.1017/S0033291719002071.
    PubMed     Text format     Abstract available


  43. CHANG WC, Wong CSM, Or PCF, Chu AOK, et al
    Inter-relationships among psychopathology, premorbid adjustment, cognition and psychosocial functioning in first-episode psychosis: a network analysis approach.
    Psychol Med. 2019 Aug 27:1-9. doi: 10.1017/S0033291719002113.
    PubMed     Text format     Abstract available


  44. ZHANG T, Yang S, Xu L, Tang X, et al
    Poor functional recovery is better predicted than conversion in studies of outcomes of clinical high risk of psychosis: insight from SHARP.
    Psychol Med. 2019 Aug 27:1-7. doi: 10.1017/S0033291719002174.
    PubMed     Text format     Abstract available


  45. LIZANO P, Dhaliwal K, Lutz O, Mothi SS, et al
    Trajectory of neurological examination abnormalities in antipsychotic-naive first-episode psychosis population: a 1 year follow-up study.
    Psychol Med. 2019 Aug 27:1-9. doi: 10.1017/S0033291719002162.
    PubMed     Text format     Abstract available


  46. CAKICI N, van Beveren NJM, Judge-Hundal G, Koola MM, et al
    An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.
    Psychol Med. 2019 Aug 23:1-13. doi: 10.1017/S0033291719001995.
    PubMed     Text format     Abstract available


  47. APPIAH-KUSI E, Wilson R, Colizzi M, Foglia E, et al
    Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids.
    Psychol Med. 2019 Aug 19:1-10. doi: 10.1017/S0033291719001946.
    PubMed     Text format     Abstract available


  48. VAN OS J, Pries LK, Delespaul P, Kenis G, et al
    Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study.
    Psychol Med. 2019 Aug 15:1-14. doi: 10.1017/S003329171900196.
    PubMed     Text format     Abstract available


  49. LEI D, Pinaya WHL, van Amelsvoort T, Marcelis M, et al
    Detecting schizophrenia at the level of the individual: relative diagnostic value of whole-brain images, connectome-wide functional connectivity and graph-based metrics.
    Psychol Med. 2019 Aug 8:1-10. doi: 10.1017/S0033291719001934.
    PubMed     Text format     Abstract available


  50. MALL S, Platt JM, Temmingh H, Musenge E, et al
    The relationship between childhood trauma and schizophrenia in the Genomics of Schizophrenia in the Xhosa people (SAX) study in South Africa.
    Psychol Med. 2019 Aug 7:1-8. doi: 10.1017/S0033291719001703.
    PubMed     Text format     Abstract available


    July 2019
  51. DAZZAN P, Lappin JM, Heslin M, Donoghue K, et al
    Symptom remission at 12-weeks strongly predicts long-term recovery from the first episode of psychosis.
    Psychol Med. 2019 Jul 31:1-11. doi: 10.1017/S0033291719001399.
    PubMed     Text format     Abstract available


  52. BIGDELI TB, Nuechterlein KH, Sugar CA, Subotnik KL, et al
    Evidence of shared familial factors influencing neurocognitive endophenotypes in adult- and childhood-onset schizophrenia.
    Psychol Med. 2019 Jul 31:1-8. doi: 10.1017/S0033291719001715.
    PubMed     Text format     Abstract available


  53. HOGERZEIL SJ, van Hemert AM
    Design choices when estimating the treated incidence of schizophrenia.
    Psychol Med. 2019 Jul 26:1-2. doi: 10.1017/S0033291719001338.
    PubMed     Text format    


  54. MORITZ S, Gaweda L, Heinz A, Gallinat J, et al
    Four reasons why early detection centers for psychosis should be renamed and their treatment targets reconsidered: we should not catastrophize a future we can neither reliably predict nor change.
    Psychol Med. 2019 Jul 24:1-7. doi: 10.1017/S0033291719001740.
    PubMed     Text format     Abstract available


  55. HARRIS MA, Shen X, Cox SR, Gibson J, et al
    Stratifying major depressive disorder by polygenic risk for schizophrenia in relation to structural brain measures.
    Psychol Med. 2019 Jul 18:1-10. doi: 10.1017/S003329171900165.
    PubMed     Text format     Abstract available


  56. KUO SS, Wojtalik JA, Mesholam-Gately RI, Keshavan MS, et al
    Transdiagnostic validity of the MATRICS Consensus Cognitive Battery across the autism-schizophrenia spectrum.
    Psychol Med. 2019 Jul 12:1-10. doi: 10.1017/S0033291719001582.
    PubMed     Text format     Abstract available


  57. TAN S, Zhu X, Fan H, Tan Y, et al
    Who will benefit from computerized cognitive remediation therapy? Evidence from a multisite randomized controlled study in schizophrenia.
    Psychol Med. 2019 Jul 12:1-11. doi: 10.1017/S0033291719001594.
    PubMed     Text format     Abstract available


  58. BORA E
    Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis.
    Psychol Med. 2019 Jul 9:1-9. doi: 10.1017/S0033291719001685.
    PubMed     Text format     Abstract available


  59. JOYCE DW, Averbeck BB, Frith CD, Shergill SS, et al
    Examining belief and confidence in schizophrenia - ADDENDUM.
    Psychol Med. 2019 Jul 8:1. doi: 10.1017/S0033291719001363.
    PubMed     Text format    


  60. VAN RHEENEN TE, Cropley V, Fagerlund B, Wannan C, et al
    Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders.
    Psychol Med. 2019 Jul 5:1-15. doi: 10.1017/S0033291719001417.
    PubMed     Text format     Abstract available


    June 2019
  61. LIU S, Li A, Liu Y, Li J, et al
    MIR137 polygenic risk is associated with schizophrenia and affects functional connectivity of the dorsolateral prefrontal cortex.
    Psychol Med. 2019 Jun 26:1-9. doi: 10.1017/S0033291719001442.
    PubMed     Text format     Abstract available


  62. RUBIO JM, Taipale H, Correll CU, Tanskanen A, et al
    Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study.
    Psychol Med. 2019 Jun 13:1-12. doi: 10.1017/S0033291719001296.
    PubMed     Text format     Abstract available


  63. NAKAHARA S, Turner JA, Calhoun VD, Lim KO, et al
    Dentate gyrus volume deficit in schizophrenia.
    Psychol Med. 2019 Jun 3:1-11. doi: 10.1017/S0033291719001144.
    PubMed     Text format     Abstract available


    May 2019
  64. AYONRINDE OA
    Cannabis and psychosis: revisiting a nineteenth century study of 'Indian Hemp and Insanity' in Colonial British India.
    Psychol Med. 2019 May 27:1-9. doi: 10.1017/S0033291719001077.
    PubMed     Text format     Abstract available


  65. SANDSTROM A, MacKenzie L, Pizzo A, Fine A, et al
    Observed psychopathology in offspring of parents with major depressive disorder, bipolar disorder and schizophrenia.
    Psychol Med. 2019 May 23:1-7. doi: 10.1017/S0033291719001089.
    PubMed     Text format     Abstract available


  66. GOLD JM, Bansal S, Gaspar JM, Chen S, et al
    People with schizophrenia show enhanced cognitive costs of maintaining a single item in working memory.
    Psychol Med. 2019 May 15:1-7. doi: 10.1017/S0033291719000862.
    PubMed     Text format     Abstract available


  67. CORSI-ZUELLI F, Loureiro CM, Shuhama R, Fachim HA, et al
    Cytokine profile in first-episode psychosis, unaffected siblings and community-based controls: the effects of familial liability and childhood maltreatment.
    Psychol Med. 2019 May 8:1-9. doi: 10.1017/S0033291719001016.
    PubMed     Text format     Abstract available


  68. AJNAKINA O, Stubbs B, Francis E, Gaughran F, et al
    Hospitalisation and length of hospital stay following first-episode psychosis: systematic review and meta-analysis of longitudinal studies.
    Psychol Med. 2019 May 6:1-11. doi: 10.1017/S0033291719000904.
    PubMed     Text format     Abstract available


  69. PIGNON B, Geoffroy PA, Thomas P, Roelandt JL, et al
    Environment risk factors have different impact on bipolar and psychotic disorders: an analysis of MHGP survey.
    Psychol Med. 2019;49:1229-1232.
    PubMed     Text format    


    April 2019
  70. PLAVEN-SIGRAY P, Cervenka S
    Meta-analytic studies of the glial cell marker TSPO in psychosis - a question of apples and pears?: A commentary on 'Neuroinflammation in schizophrenia: metaanalysis of in-vivo microglial imaging' by Marques et al. - ERRATUM.
    Psychol Med. 2019 Apr 30:1-2. doi: 10.1017/S0033291719000746.
    PubMed     Text format    


  71. LASSILA M, Nordstrom T, Hurtig T, Maki P, et al
    School success in childhood and subsequent prodromal symptoms and psychoses in the Northern Finland Birth Cohort 1986.
    Psychol Med. 2019 Apr 23:1-8. doi: 10.1017/S0033291719000825.
    PubMed     Text format     Abstract available


  72. KIRSCHNER M, Cathomas F, Manoliu A, Habermeyer B, et al
    Shared and dissociable features of apathy and reward system dysfunction in bipolar I disorder and schizophrenia.
    Psychol Med. 2019 Apr 17:1-12. doi: 10.1017/S0033291719000801.
    PubMed     Text format     Abstract available


  73. BRADLEY ER, Brustkern J, De Coster L, van den Bos W, et al
    Victory is its own reward: oxytocin increases costly competitive behavior in schizophrenia.
    Psychol Med. 2019 Apr 4:1-9. doi: 10.1017/S0033291719000552.
    PubMed     Text format     Abstract available


    March 2019
  74. OLESEN JA, Posselt CM, Poulsen CH, Nordentoft M, et al
    Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls.
    Psychol Med. 2019 Mar 18:1-8. doi: 10.1017/S0033291719000370.
    PubMed     Text format     Abstract available


  75. RYDKJAER J, Jepsen JRM, Pagsberg AK, Fagerlund B, et al
    Do young adolescents with first-episode psychosis or ADHD show sensorimotor gating deficits?
    Psychol Med. 2019 Mar 15:1-9. doi: 10.1017/S0033291719000412.
    PubMed     Text format     Abstract available


  76. GLAUSIER JR, Kelly MA, Salem S, Chen K, et al
    Proxy measures of premortem cognitive aptitude in postmortem subjects with schizophrenia.
    Psychol Med. 2019 Mar 14:1-8. doi: 10.1017/S0033291719000382.
    PubMed     Text format     Abstract available


  77. STEEN NE, Dieset I, Hope S, Vedal TSJ, et al
    Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders.
    Psychol Med. 2019 Mar 14:1-12. doi: 10.1017/S0033291719000400.
    PubMed     Text format     Abstract available


  78. ISVORANU AM, Guloksuz S, Epskamp S, van Os J, et al
    Toward incorporating genetic risk scores into symptom networks of psychosis.
    Psychol Med. 2019 Mar 14:1-8. doi: 10.1017/S003329171900045.
    PubMed     Text format     Abstract available


  79. HAINING K, Matrunola C, Mitchell L, Gajwani R, et al
    Neuropsychological deficits in participants at clinical high risk for psychosis recruited from the community: relationships to functioning and clinical symptoms.
    Psychol Med. 2019 Mar 13:1-9. doi: 10.1017/S0033291718003975.
    PubMed     Text format     Abstract available


  80. CARRA G, Crocamo C, Bartoli F, Angermeyer M, et al
    The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling.
    Psychol Med. 2019 Mar 8:1-9. doi: 10.1017/S0033291719000321.
    PubMed     Text format     Abstract available


  81. WEISER M, Fenchel D, Frenkel O, Fruchter E, et al
    Understanding the association between advanced paternal age and schizophrenia and bipolar disorder.
    Psychol Med. 2019 Mar 4:1-7. doi: 10.1017/S0033291719000242.
    PubMed     Text format     Abstract available


    February 2019
  82. DI BIASE MA, Zhang F, Lyall A, Kubicki M, et al
    Neuroimaging auditory verbal hallucinations in schizophrenia patient and healthy populations.
    Psychol Med. 2019 Feb 20:1-10. doi: 10.1017/S0033291719000205.
    PubMed     Text format     Abstract available


  83. ZHANG L, Ai H, Opmeer EM, Marsman JC, et al
    Distinct temporal brain dynamics in bipolar disorder and schizophrenia during emotion regulation.
    Psychol Med. 2019 Feb 18:1-9. doi: 10.1017/S0033291719000217.
    PubMed     Text format     Abstract available


  84. JAUHAR S, Laws KR, McKenna PJ
    CBT for schizophrenia: a critical viewpoint.
    Psychol Med. 2019 Feb 13:1-4. doi: 10.1017/S0033291718004166.
    PubMed     Text format    


  85. PLAVEN-SIGRAY P, Cervenka S
    Meta-analytic studies of the glial cell marker TSPO in psychosis - a question of apples and pears?
    Psychol Med. 2019 Feb 11:1-5. doi: 10.1017/S003329171800421.
    PubMed     Text format    


  86. SELTEN JP, van der Ven E, Termorshuizen F
    Migration and psychosis: a meta-analysis of incidence studies.
    Psychol Med. 2019 Feb 6:1-11. doi: 10.1017/S0033291719000035.
    PubMed     Text format     Abstract available


    January 2019
  87. VAN HAREN NEM, Van Dam DS, Stellato RK
    Change in IQ in schizophrenia patients and their siblings: a controlled longitudinal study.
    Psychol Med. 2019 Jan 24:1-9. doi: 10.1017/S0033291718003537.
    PubMed     Text format     Abstract available


  88. WULFF S, Nielsen MO, Rostrup E, Svarer C, et al
    The relation between dopamine D2 receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients.
    Psychol Med. 2019 Jan 15:1-9. doi: 10.1017/S0033291718004099.
    PubMed     Text format     Abstract available


  89. MCCLEERY A, Mathalon DH, Wynn JK, Roach BJ, et al
    Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm.
    Psychol Med. 2019 Jan 15:1-12. doi: 10.1017/S0033291718004087.
    PubMed     Text format     Abstract available


  90. PEH OH, Rapisarda A, Lee J
    Childhood adversities in people at ultra-high risk (UHR) for psychosis: a systematic review and meta-analysis.
    Psychol Med. 2019 Jan 8:1-13. doi: 10.1017/S003329171800394.
    PubMed     Text format     Abstract available


  91. NUECHTERLEIN KH, Subotnik KL, Ventura J, Turner LR, et al
    Enhancing return to work or school after a first episode of schizophrenia: the UCLA RCT of Individual Placement and Support and Workplace Fundamentals Module training.
    Psychol Med. 2019 Jan 4:1-9. doi: 10.1017/S0033291718003860.
    PubMed     Text format     Abstract available


  92. LAW SF, Luo X, Yao S, Wang X, et al
    Assertive Community Treatment in China - it is time for a made-in-China solution.
    Psychol Med. 2019;49:172-174.
    PubMed     Text format    


  93. FIRN M, Alonso-Vicente M, Hubbeling D
    The Ferrari v. the bicycle.
    Psychol Med. 2019;49:170-171.
    PubMed     Text format    


    December 2018
  94. AJNAKINA O, David AS, Murray RM
    'At risk mental state' clinics for psychosis - an idea whose time has come - and gone!
    Psychol Med. 2018 Dec 26:1-6. doi: 10.1017/S0033291718003859.
    PubMed     Text format     Abstract available


  95. BUTLER R, Berry K, Varese F, Bucci S, et al
    Are family warmth and positive remarks related to outcomes in psychosis? A systematic review.
    Psychol Med. 2018 Dec 20:1-16. doi: 10.1017/S0033291718003768.
    PubMed     Text format     Abstract available


  96. QUIDE Y, Bortolasci CC, Spolding B, Kidnapillai S, et al
    Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder.
    Psychol Med. 2018 Dec 18:1-9. doi: 10.1017/S0033291718003690.
    PubMed     Text format     Abstract available


  97. EBDRUP BH, Axelsen MC, Bak N, Fagerlund B, et al
    Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naive schizophrenia patients.
    Psychol Med. 2018 Dec 18:1-10. doi: 10.1017/S0033291718003781.
    PubMed     Text format     Abstract available


  98. DYKXHOORN J, Hollander AC, Lewis G, Magnusson C, et al
    Risk of schizophrenia, schizoaffective, and bipolar disorders by migrant status, region of origin, and age-at-migration: a national cohort study of 1.8 million people.
    Psychol Med. 2018 Dec 5:1-10. doi: 10.1017/S0033291718003227.
    PubMed     Text format     Abstract available


  99. WANNAN CMJ, Cropley VL, Chakravarty MM, Van Rheenen TE, et al
    Hippocampal subfields and visuospatial associative memory across stages of schizophrenia-spectrum disorder.
    Psychol Med. 2018 Dec 4:1-11. doi: 10.1017/S0033291718003458.
    PubMed     Text format     Abstract available


    November 2018
  100. KIM S, Jung WH, Howes OD, Veronese M, et al
    Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [18F]DOPA PET and fMRI study.
    Psychol Med. 2018 Nov 21:1-10. doi: 10.1017/S0033291718003471.
    PubMed     Text format     Abstract available


  101. RODRIGUEZ V, Ajnakina O, Stilo SA, Mondelli V, et al
    Jumping to conclusions at first onset of psychosis predicts longer admissions, more compulsory admissions and police involvement over the next 4 years: the GAP study.
    Psychol Med. 2018 Nov 5:1-11. doi: 10.1017/S0033291718003197.
    PubMed     Text format     Abstract available


    October 2018
  102. HUI CL, Honer WG, Lee EH, Chang WC, et al
    Predicting first-episode psychosis patients who will never relapse over 10 years.
    Psychol Med. 2018 Oct 30:1-9. doi: 10.1017/S0033291718003070.
    PubMed     Text format     Abstract available


  103. MARQUES TR, Ashok AH, Pillinger T, Veronese M, et al
    Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies.
    Psychol Med. 2018 Oct 25:1-11. doi: 10.1017/S0033291718003057.
    PubMed     Text format     Abstract available


  104. KRAVARITI E, Demjaha A, Zanelli J, Ibrahim F, et al
    Neuropsychological function at first episode in treatment-resistant psychosis: findings from the AESOP-10 study.
    Psychol Med. 2018 Oct 23:1-11. doi: 10.1017/S0033291718002957.
    PubMed     Text format     Abstract available


  105. ANDERSON KK, Norman R, MacDougall AG, Edwards J, et al
    Estimating the incidence of first-episode psychosis using population-based health administrative data to inform early psychosis intervention services.
    Psychol Med. 2018 Oct 12:1-9. doi: 10.1017/S0033291718002933.
    PubMed     Text format     Abstract available


  106. MALLARD TT, Harden KP, Fromme K
    Genetic risk for schizophrenia is associated with substance use in emerging adulthood: an event-level polygenic prediction model.
    Psychol Med. 2018 Oct 12:1-9. doi: 10.1017/S0033291718002817.
    PubMed     Text format     Abstract available


  107. RADHAKRISHNAN R, Guloksuz S, Ten Have M, de Graaf R, et al
    Interaction between environmental and familial affective risk impacts psychosis admixture in states of affective dysregulation.
    Psychol Med. 2018 Oct 4:1-11. doi: 10.1017/S0033291718002635.
    PubMed     Text format     Abstract available


  108. QUATTRONE D, Di Forti M, Gayer-Anderson C, Ferraro L, et al
    Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study.
    Psychol Med. 2018 Oct 4:1-14. doi: 10.1017/S0033291718002131.
    PubMed     Text format     Abstract available


  109. CASSETTA BD, Tomfohr-Madsen LM, Goghari VM
    A randomized controlled trial of working memory and processing speed training in schizophrenia.
    Psychol Med. 2018 Oct 3:1-11. doi: 10.1017/S0033291718002775.
    PubMed     Text format     Abstract available


    September 2018
  110. MATHALON DH, Roach BJ, Ferri JM, Loewy RL, et al
    Deficient auditory predictive coding during vocalization in the psychosis risk syndrome and in early illness schizophrenia: the final expanded sample.
    Psychol Med. 2018 Sep 25:1-8. doi: 10.1017/S0033291718002659.
    PubMed     Text format     Abstract available


  111. WOODROW A, Sparks S, Bobrovskaia V, Paterson C, et al
    Decision-making ability in psychosis: a systematic review and meta-analysis of the magnitude, specificity and correlates of impaired performance on the Iowa and Cambridge Gambling Tasks.
    Psychol Med. 2018 Sep 24:1-17. doi: 10.1017/S0033291718002660.
    PubMed     Text format     Abstract available


  112. PALANIYAPPAN L, Al-Radaideh A, Mougin O, Das T, et al
    Aberrant myelination of the cingulum and Schneiderian delusions in schizophrenia: a 7T magnetization transfer study.
    Psychol Med. 2018 Sep 19:1-7. doi: 10.1017/S0033291718002647.
    PubMed     Text format     Abstract available


  113. CHU AOK, Chang WC, Chan SKW, Lee EHM, et al
    Comparison of cognitive functions between first-episode schizophrenia patients, their unaffected siblings and individuals at clinical high-risk for psychosis.
    Psychol Med. 2018 Sep 18:1-8. doi: 10.1017/S0033291718002726.
    PubMed     Text format     Abstract available


  114. ZHANG T, Xu L, Tang Y, Li H, et al
    Prediction of psychosis in prodrome: development and validation of a simple, personalized risk calculator.
    Psychol Med. 2018 Sep 14:1-9. doi: 10.1017/S0033291718002738.
    PubMed     Text format     Abstract available


  115. STRAUSS GP, Granholm E, Holden JL, Ruiz I, et al
    The effects of combined oxytocin and cognitive behavioral social skills training on social cognition in schizophrenia.
    Psychol Med. 2018 Sep 5:1-9. doi: 10.1017/S0033291718002465.
    PubMed     Text format     Abstract available


  116. ADDINGTON J, Stowkowy J, Liu L, Cadenhead KS, et al
    Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis.
    Psychol Med. 2018 Sep 4:1-8. doi: 10.1017/S0033291718002258.
    PubMed     Text format     Abstract available


  117. DESAI M, Wooller A, Lignugaris A, Gopal S, et al
    Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
    Psychol Med. 2018;48:2098-2099.
    PubMed     Text format    


    August 2018
  118. RAMSAY H, Barnett JH, Murray GK, Miettunen J, et al
    Cognition, psychosis risk and metabolic measures in two adolescent birth cohorts - CORRIGENDUM.
    Psychol Med. 2018 Aug 30:1. doi: 10.1017/S0033291718002192.
    PubMed     Text format    


  119. RABAGLIATI H, Delaney-Busch N, Snedeker J, Kuperberg G, et al
    Spared bottom-up but impaired top-down interactive effects during naturalistic language processing in schizophrenia: evidence from the visual-world paradigm.
    Psychol Med. 2018 Aug 22:1-11. doi: 10.1017/S0033291718001952.
    PubMed     Text format     Abstract available


  120. FIKSINSKI AM, Breetvelt EJ, Lee YJ, Boot E, et al
    Neurocognition and adaptive functioning in a genetic high risk model of schizophrenia.
    Psychol Med. 2018 Aug 1:1-8. doi: 10.1017/S0033291718001824.
    PubMed     Text format     Abstract available


  121. STAFFORD J, Howard R, Kirkbride JB
    The incidence of very late-onset psychotic disorders: a systematic review and meta-analysis, 1960-2016.
    Psychol Med. 2018;48:1775-1786.
    PubMed     Text format     Abstract available


  122. DOCHERTY AR, Moscati A, Dick D, Savage JE, et al
    Polygenic prediction of the phenome, across ancestry, in emerging adulthood.
    Psychol Med. 2018;48:1814-1823.
    PubMed     Text format     Abstract available


    July 2018
  123. SO HC, Chau KL, Ao FK, Mo CH, et al
    Exploring shared genetic bases and causal relationships of schizophrenia and bipolar disorder with 28 cardiovascular and metabolic traits.
    Psychol Med. 2018 Jul 26:1-13. doi: 10.1017/S0033291718001812.
    PubMed     Text format     Abstract available


  124. RAMSAY H, Barnett JH, Murray GK, Miettunen J, et al
    Cognition, psychosis risk and metabolic measures in two adolescent birth cohorts.
    Psychol Med. 2018 Jul 24:1-15. doi: 10.1017/S0033291718001794.
    PubMed     Text format     Abstract available


  125. LUO X, Law SF, Wang X, Shi J, et al
    Effectiveness of an Assertive Community Treatment program for people with severe schizophrenia in mainland China - a 12-month randomized controlled trial.
    Psychol Med. 2018 Jul 2:1-11. doi: 10.1017/S0033291718001629.
    PubMed     Text format     Abstract available


  126. IKEDA M, Tanaka S, Saito T, Ozaki N, et al
    Re-evaluating classical body type theories: genetic correlation between psychiatric disorders and body mass index.
    Psychol Med. 2018;48:1745-1748.
    PubMed     Text format    


  127. PATEL R, Chesney E, Taylor M, Taylor D, et al
    Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
    Psychol Med. 2018;48:1616-1623.
    PubMed     Text format     Abstract available


    June 2018
  128. CIARLEGLIO AJ, Brucato G, Masucci MD, Altschuler R, et al
    A predictive model for conversion to psychosis in clinical high-risk patients.
    Psychol Med. 2018 Jun 28:1-10. doi: 10.1017/S003329171800171.
    PubMed     Text format     Abstract available


  129. KRUIPER C, Fagerlund B, Nielsen MO, During S, et al
    Associations between P3a and P3b amplitudes and cognition in antipsychotic-naive first-episode schizophrenia patients.
    Psychol Med. 2018 Jun 19:1-8. doi: 10.1017/S0033291718001575.
    PubMed     Text format     Abstract available


  130. KISHI T, Ikuta T, Matsui Y, Inada K, et al
    Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis.
    Psychol Med. 2018 Jun 18:1-8. doi: 10.1017/S0033291718001393.
    PubMed     Text format     Abstract available


  131. LEMMERS-JANSEN ILJ, Fett AJ, Hanssen E, Veltman DJ, et al
    Learning to trust: social feedback normalizes trust behavior in first-episode psychosis and clinical high risk.
    Psychol Med. 2018 Jun 13:1-11. doi: 10.1017/S003329171800140.
    PubMed     Text format     Abstract available


  132. HARTMANN JA, Nelson B, Ratheesh A, Treen D, et al
    At-risk studies and clinical antecedents of psychosis, bipolar disorder and depression: a scoping review in the context of clinical staging.
    Psychol Med. 2018 Jun 4:1-13. doi: 10.1017/S0033291718001435.
    PubMed     Text format     Abstract available


    May 2018
  133. TAKAYANAGI Y, Sasabayashi D, Takahashi T, Komori Y, et al
    Altered brain gyrification in deficit and non-deficit schizophrenia.
    Psychol Med. 2018 May 9:1-8. doi: 10.1017/S0033291718001228.
    PubMed     Text format     Abstract available


  134. JESSEN K, Rostrup E, Mandl RCW, Nielsen MO, et al
    Cortical structures and their clinical correlates in antipsychotic-naive schizophrenia patients before and after 6 weeks of dopamine D2/3 receptor antagonist treatment.
    Psychol Med. 2018 May 8:1-10. doi: 10.1017/S0033291718001198.
    PubMed     Text format     Abstract available


  135. HALLGREN M, Skott M, Ekblom O, Firth J, et al
    Exercise effects on cognitive functioning in young adults with first-episode psychosis: FitForLife.
    Psychol Med. 2018 May 6:1-9. doi: 10.1017/S0033291718001022.
    PubMed     Text format     Abstract available


  136. PALANIYAPPAN L, Hodgson O, Balain V, Iwabuchi S, et al
    Structural covariance and cortical reorganisation in schizophrenia: a MRI-based morphometric study.
    Psychol Med. 2018 May 6:1-9. doi: 10.1017/S0033291718001010.
    PubMed     Text format     Abstract available


  137. LUTGENS D, Joober R, Iyer S, Lepage M, et al
    Progress of negative symptoms over the initial 5 years of a first episode of psychosis - CORRIGENDUM.
    Psychol Med. 2018 May 2:1-3. doi: 10.1017/S0033291718000843.
    PubMed     Text format    


  138. JONSSON BH, Winzer R, Gornitzki C
    Letter to the Editor: Are older studies lost in database searches for systematic reviews?
    Psychol Med. 2018;48:1218-1219.
    PubMed     Text format    


    April 2018
  139. MINOR KS, Willits JA, Marggraf MP, Jones MN, et al
    Measuring disorganized speech in schizophrenia: automated analysis explains variance in cognitive deficits beyond clinician-rated scales.
    Psychol Med. 2018 Apr 25:1-9. doi: 10.1017/S0033291718001046.
    PubMed     Text format     Abstract available


  140. DE JONG S, van Donkersgoed RJM, Timmerman ME, Aan Het Rot M, et al
    Metacognitive reflection and insight therapy (MERIT) for patients with schizophrenia.
    Psychol Med. 2018 Apr 25:1-11. doi: 10.1017/S0033291718000855.
    PubMed     Text format     Abstract available


  141. GUNNARSDOTTIR ED, Hallgren J, Hultman CM, McNeil TF, et al
    Risk of neurological, eye and ear disease in offspring to parents with schizophrenia or depression compared with offspring to healthy parents.
    Psychol Med. 2018 Apr 19:1-7. doi: 10.1017/S0033291718000338.
    PubMed     Text format     Abstract available


  142. KAPPELMANN N, Khandaker GM, Dal H, Stochl J, et al
    Systemic inflammation and intelligence in early adulthood and subsequent risk of schizophrenia and other non-affective psychoses: a longitudinal cohort and co-relative study.
    Psychol Med. 2018 Apr 6:1-8. doi: 10.1017/S0033291718000831.
    PubMed     Text format     Abstract available


  143. JAASKELAINEN E, Juola T, Korpela H, Lehtiniemi H, et al
    Epidemiology of psychotic depression - systematic review and meta-analysis.
    Psychol Med. 2018;48:905-918.
    PubMed     Text format     Abstract available


    March 2018
  144. BARLATI S, Deste G, Gregorelli M, Vita A, et al
    Autistic traits in a sample of adult patients with schizophrenia: prevalence and correlates.
    Psychol Med. 2018 Mar 20:1-9. doi: 10.1017/S0033291718000600.
    PubMed     Text format     Abstract available


  145. LUTGENS D, Joober R, Iyer S, Lepage M, et al
    Progress of negative symptoms over the initial 5 years of a first episode of psychosis.
    Psychol Med. 2018 Mar 14:1-9. doi: 10.1017/S003329171800048.
    PubMed     Text format     Abstract available


  146. HEUVELMAN H, Nazroo J, Rai D
    Investigating ethnic variations in reporting of psychotic symptoms: a multiple-group confirmatory factor analysis of the Psychosis Screening Questionnaire.
    Psychol Med. 2018 Mar 12:1-9. doi: 10.1017/S0033291718000399.
    PubMed     Text format     Abstract available


  147. STABLEIN M, Storchak H, Ghinea D, Kraft D, et al
    Visual working memory encoding in schizophrenia and first-degree relatives: neurofunctional abnormalities and impaired consolidation.
    Psychol Med. 2018 Mar 9:1-9. doi: 10.1017/S003329171800051.
    PubMed     Text format     Abstract available


  148. BECK AT, Himelstein R, Bredemeier K, Silverstein SM, et al
    What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors.
    Psychol Med. 2018 Mar 4:1-10. doi: 10.1017/S0033291718000442.
    PubMed     Text format     Abstract available


  149. ESCOTT-PRICE V, Smith DJ, Kendall K, Ward J, et al
    Polygenic risk for schizophrenia and season of birth within the UK Biobank cohort.
    Psychol Med. 2018 Mar 4:1-6. doi: 10.1017/S0033291718000454.
    PubMed     Text format     Abstract available


  150. WATERS F, Blom JD, Jardri R, Hugdahl K, et al
    Auditory hallucinations, not necessarily a hallmark of psychotic disorder.
    Psychol Med. 2018;48:529-536.
    PubMed     Text format     Abstract available


    February 2018
  151. FERNANDEZ-EGEA E, Worbe Y, Bernardo M, Robbins TW, et al
    Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia.
    Psychol Med. 2018 Feb 19:1-8. doi: 10.1017/S003329171800017.
    PubMed     Text format     Abstract available


  152. FERRI J, Ford JM, Roach BJ, Turner JA, et al
    Resting-state thalamic dysconnectivity in schizophrenia and relationships with symptoms.
    Psychol Med. 2018 Feb 15:1-8. doi: 10.1017/S003329171800003.
    PubMed     Text format     Abstract available


  153. VANES LD, Mouchlianitis E, Collier T, Averbeck BB, et al
    Differential neural reward mechanisms in treatment-responsive and treatment-resistant schizophrenia.
    Psychol Med. 2018 Feb 14:1-10. doi: 10.1017/S0033291718000041.
    PubMed     Text format     Abstract available


  154. BORA E, Akdede BB, Alptekin K
    The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis - CORRIGENDUM.
    Psychol Med. 2018 Feb 8:1. doi: 10.1017/S0033291717003932.
    PubMed     Text format    


  155. BORA E
    A neurodevelopment and neuroplasticity-based framework for early intervention in psychotic disorders.
    Psychol Med. 2018;48:353-361.
    PubMed     Text format     Abstract available


  156. NYBERG J, Henriksson M, Aberg MAI, Rosengren A, et al
    Cardiovascular fitness in late adolescent males and later risk of serious non-affective mental disorders: a prospective, population-based study.
    Psychol Med. 2018;48:416-425.
    PubMed     Text format     Abstract available


    January 2018
  157. VISSER KF, Esfahlani FZ, Sayama H, Strauss GP, et al
    An ecological momentary assessment evaluation of emotion regulation abnormalities in schizophrenia.
    Psychol Med. 2018 Jan 24:1-9. doi: 10.1017/S0033291717003865.
    PubMed     Text format     Abstract available


  158. PADULA MC, Schaer M, Armando M, Sandini C, et al
    Cortical morphology development in patients with 22q11.2 deletion syndrome at ultra-high risk of psychosis.
    Psychol Med. 2018 Jan 17:1-9. doi: 10.1017/S0033291717003920.
    PubMed     Text format     Abstract available


  159. ZWICKER A, Denovan-Wright EM, Uher R
    Gene-environment interplay in the etiology of psychosis.
    Psychol Med. 2018 Jan 15:1-12. doi: 10.1017/S003329171700383.
    PubMed     Text format     Abstract available


  160. BALLESTEROS A, Sanchez-Torres AM, Lopez-Ilundain JM, Cabrera B, et al
    Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
    Psychol Med. 2018 Jan 14:1-10. doi: 10.1017/S0033291717003774.
    PubMed     Text format     Abstract available


  161. GRANT PM, Perivoliotis D, Luther L, Bredemeier K, et al
    Rapid improvement in beliefs, mood, and performance following an experimental success experience in an analogue test of recovery-oriented cognitive therapy.
    Psychol Med. 2018;48:261-268.
    PubMed     Text format     Abstract available


  162. WANNAN CMJ, Bartholomeusz CF, Cropley VL, Van Rheenen TE, et al
    Deterioration of visuospatial associative memory following a first psychotic episode: a long-term follow-up study.
    Psychol Med. 2018;48:132-141.
    PubMed     Text format     Abstract available


    December 2017
  163. KILIAN S, Asmal L, Chiliza B, Olivier MR, et al
    Childhood adversity and cognitive function in schizophrenia spectrum disorders and healthy controls: evidence for an association between neglect and social cognition.
    Psychol Med. 2017 Dec 22:1-8. doi: 10.1017/S0033291717003671.
    PubMed     Text format     Abstract available


  164. RIGLIN L, Collishaw S, Richards A, Thapar AK, et al
    The impact of schizophrenia and mood disorder risk alleles on emotional problems: investigating change from childhood to middle age.
    Psychol Med. 2017 Dec 14:1-6. doi: 10.1017/S0033291717003634.
    PubMed     Text format     Abstract available


  165. RANNING A, Laursen T, Agerbo E, Thorup A, et al
    School performance from primary education in the adolescent offspring of parents with schizophrenia and bipolar disorder- a national, register-based study.
    Psychol Med. 2017 Dec 14:1-8. doi: 10.1017/S0033291717003518.
    PubMed     Text format     Abstract available


  166. SILVERSTEIN SM, Paterno D, Cherneski L, Green S, et al
    Optical coherence tomography indices of structural retinal pathology in schizophrenia.
    Psychol Med. 2017 Dec 13:1-11. doi: 10.1017/S0033291717003555.
    PubMed     Text format     Abstract available


  167. HUFNER K, Brugger H, Kuster E, Dunsser F, et al
    Isolated psychosis during exposure to very high and extreme altitude - characterisation of a new medical entity.
    Psychol Med. 2017 Dec 5:1-8. doi: 10.1017/S0033291717003397.
    PubMed     Text format     Abstract available


    November 2017
  168. OKRUSZEK L, Wordecha M, Jarkiewicz M, Kossowski B, et al
    Brain correlates of recognition of communicative interactions from biological motion in schizophrenia.
    Psychol Med. 2017 Nov 27:1-10. doi: 10.1017/S0033291717003385.
    PubMed     Text format     Abstract available


  169. ZHANG T, Xu L, Tang Y, Cui H, et al
    Duration of untreated prodromal symptoms in a Chinese sample at a high risk for psychosis: demographic, clinical, and outcome.
    Psychol Med. 2017 Nov 27:1-8. doi: 10.1017/S0033291717002707.
    PubMed     Text format     Abstract available


  170. ALLOTT K, Fraguas D, Bartholomeusz CF, Diaz-Caneja CM, et al
    Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis.
    Psychol Med. 2017 Nov 27:1-18. doi: 10.1017/S0033291717003002.
    PubMed     Text format     Abstract available


  171. BLAKEY R, Ranlund S, Zartaloudi E, Cahn W, et al
    Associations between psychosis endophenotypes across brain functional, structural, and cognitive domains.
    Psychol Med. 2017 Nov 2:1-20. doi: 10.1017/S0033291717002860.
    PubMed     Text format     Abstract available


    October 2017
  172. ZOGHBI AW, Lieberman JA
    Alive but not well: the limited validity but continued utility of the concept of schizophrenia.
    Psychol Med. 2017 Oct 26:1-2. doi: 10.1017/S0033291717001969.
    PubMed     Text format     Abstract available


  173. KAHN RS
    Why the concept of schizophrenia is still alive and kicking.
    Psychol Med. 2017 Oct 26:1-2. doi: 10.1017/S0033291717002069.
    PubMed     Text format    


  174. NEILSON E, Bois C, Clarke TK, Hall L, et al
    Polygenic risk for schizophrenia, transition and cortical gyrification: a high-risk study.
    Psychol Med. 2017 Oct 25:1-11. doi: 10.1017/S0033291717003087.
    PubMed     Text format     Abstract available


  175. MUCCI A, Galderisi S, Green MF, Nuechterlein K, et al
    Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives.
    Psychol Med. 2017 Oct 11:1-10. doi: 10.1017/S0033291717002902.
    PubMed     Text format     Abstract available


  176. XIE DJ, Lui SSY, Geng FL, Yang ZY, et al
    Dissociation between affective experience and motivated behaviour in schizophrenia patients and their unaffected first-degree relatives and schizotypal individuals.
    Psychol Med. 2017 Oct 11:1-13. doi: 10.1017/S0033291717002926.
    PubMed     Text format     Abstract available


  177. AAS M, Melle I, Bettella F, Djurovic S, et al
    Psychotic patients who used cannabis frequently before illness onset have higher genetic predisposition to schizophrenia than those who did not.
    Psychol Med. 2017 Oct 2:1-7. doi: 10.1017/S0033291717001209.
    PubMed     Text format     Abstract available


    September 2017
  178. LU Y, Pouget JG, Andreassen OA, Djurovic S, et al
    Genetic risk scores and family history as predictors of schizophrenia in Nordic registers.
    Psychol Med. 2017 Sep 25:1-9. doi: 10.1017/S0033291717002665.
    PubMed     Text format     Abstract available


  179. DONOHOE G, Dillon R, Hargreaves A, Mothersill O, et al
    Effectiveness of a low support, remotely accessible, cognitive remediation training programme for chronic psychosis: cognitive, functional and cortical outcomes from a single blind randomised controlled trial.
    Psychol Med. 2017 Sep 21:1-14. doi: 10.1017/S0033291717001982.
    PubMed     Text format     Abstract available


  180. GAUGHRAN F, Lally J, Beck K, McCormack R, et al
    Brain-relevant antibodies in first-episode psychosis: a matched case-control study.
    Psychol Med. 2017 Sep 18:1-9. doi: 10.1017/S0033291717002689.
    PubMed     Text format     Abstract available


  181. TIN LNW, Lui SSY, Ho KKY, Hung KSY, et al
    High-functioning autism patients share similar but more severe impairments in verbal theory of mind than schizophrenia patients.
    Psychol Med. 2017 Sep 18:1-12. doi: 10.1017/S0033291717002690.
    PubMed     Text format     Abstract available


  182. CULBRETH AJ, Moran EK, Barch DM
    Effort-cost decision-making in psychosis and depression: could a similar behavioral deficit arise from disparate psychological and neural mechanisms?
    Psychol Med. 2017 Sep 11:1-16. doi: 10.1017/S0033291717002525.
    PubMed     Text format     Abstract available


  183. SCHULTZE-LUTTER F, Michel C, Ruhrmann S, Schimmelmann BG, et al
    Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community.
    Psychol Med. 2017 Sep 11:1-15. doi: 10.1017/S0033291717002586.
    PubMed     Text format     Abstract available


  184. REEDER C, Huddy V, Cella M, Taylor R, et al
    A new generation computerised metacognitive cognitive remediation programme for schizophrenia (CIRCuiTS): a randomised controlled trial.
    Psychol Med. 2017 Sep 4:1-11. doi: 10.1017/S0033291717001234.
    PubMed     Text format     Abstract available


    August 2017
  185. CURTIS D, Derks EM
    Letter to the Editor: Schizophrenia does not represent the extreme of a normally distributed trait.
    Psychol Med. 2017 Aug 29:1-2. doi: 10.1017/S0033291717002422.
    PubMed     Text format    


  186. BORA E
    Letter to the Editor: The half-alive concept of schizophrenia is still better than the spectrum of everything.
    Psychol Med. 2017 Aug 29:1-2. doi: 10.1017/S0033291717002446.
    PubMed     Text format    


  187. LEROY A, Petyt G, Pignon B, Vaiva G, et al
    Research Letter: Auto-activation deficit in schizophrenia: a case report.
    Psychol Med. 2017 Aug 24:1-3. doi: 10.1017/S0033291717002252.
    PubMed     Text format    


  188. DEGNAN A, Baker S, Edge D, Nottidge W, et al
    The nature and efficacy of culturally-adapted psychosocial interventions for schizophrenia: a systematic review and meta-analysis.
    Psychol Med. 2017 Aug 23:1-14. doi: 10.1017/S0033291717002264.
    PubMed     Text format     Abstract available


  189. SERPA MH, Doshi J, Erus G, Chaim-Avancini TM, et al
    State-dependent microstructural white matter changes in drug-naive patients with first-episode psychosis.
    Psychol Med. 2017 Aug 22:1-15. doi: 10.1017/S0033291717001015.
    PubMed     Text format     Abstract available


  190. DIMITRAKOPOULOS S, Vitoratou S, Mougiakos T, Bogeas N, et al
    Steinberg and Durell (1968) revisited: increased rates of First Episode Psychosis following military induction in Greek Army Recruits.
    Psychol Med. 2017 Aug 22:1-9. doi: 10.1017/S0033291717002276.
    PubMed     Text format     Abstract available


  191. BOUSMAN CA, Cropley V, Klauser P, Hess JL, et al
    Neuregulin-1 (NRG1) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia.
    Psychol Med. 2017 Aug 22:1-9. doi: 10.1017/S0033291717002173.
    PubMed     Text format     Abstract available


  192. CURTIS D
    Association between smoking and psychosis may be mediated by maternal smoking during pregnancy.
    Psychol Med. 2017 Aug 14:1. doi: 10.1017/S0033291717002240.
    PubMed     Text format    


  193. HUANG X, Fox KR, Ribeiro JD, Franklin JC, et al
    Psychosis as a risk factor for suicidal thoughts and behaviors: a meta-analysis of longitudinal studies.
    Psychol Med. 2017 Aug 14:1-12. doi: 10.1017/S0033291717002136.
    PubMed     Text format     Abstract available


  194. REICHERT A, Jacobs R
    Socioeconomic inequalities in duration of untreated psychosis: evidence from administrative data in England.
    Psychol Med. 2017 Aug 14:1-12. doi: 10.1017/S0033291717002197.
    PubMed     Text format     Abstract available


    July 2017
  195. RUS-CALAFELL M, Garety P, Sason E, Craig TJK, et al
    Virtual reality in the assessment and treatment of psychosis: a systematic review of its utility, acceptability and effectiveness.
    Psychol Med. 2017 Jul 24:1-30. doi: 10.1017/S0033291717001945.
    PubMed     Text format     Abstract available


  196. MOLLON J, Reichenberg A
    Cognitive development prior to onset of psychosis.
    Psychol Med. 2017 Jul 24:1-12. doi: 10.1017/S0033291717001970.
    PubMed     Text format     Abstract available


  197. DREIER JW, Berg-Beckhoff G, Andersen AMN, Susser E, et al
    Fever and infections during pregnancy and psychosis-like experiences in the offspring at age 11. A prospective study within the Danish National Birth Cohort.
    Psychol Med. 2017 Jul 24:1-11. doi: 10.1017/S0033291717001805.
    PubMed     Text format     Abstract available


  198. FIRTH J, Stubbs B, Sarris J, Rosenbaum S, et al
    The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis - CORRIGENDUM.
    Psychol Med. 2017 Jul 17:1. doi: 10.1017/S0033291717001866.
    PubMed     Text format    


  199. JEPSEN JRM, Rydkjaer J, Fagerlund B, Pagsberg AK, et al
    Overlapping and disease specific trait, response, and reflection impulsivity in adolescents with first-episode schizophrenia spectrum disorders or attention-deficit/hyperactivity disorder.
    Psychol Med. 2017 Jul 17:1-13. doi: 10.1017/S0033291717001921.
    PubMed     Text format     Abstract available


  200. GULOKSUZ S, van Os J
    The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum.
    Psychol Med. 2017 Jul 10:1-16. doi: 10.1017/S0033291717001775.
    PubMed     Text format     Abstract available


    June 2017
  201. PAKSARIAN D, Trabjerg BB, Merikangas KR, Mors O, et al
    The role of genetic liability in the association of urbanicity at birth and during upbringing with schizophrenia in Denmark.
    Psychol Med. 2017 Jun 29:1-10. doi: 10.1017/S0033291717001696.
    PubMed     Text format     Abstract available


  202. CUI Y, Liu B, Song M, Lipnicki DM, et al
    Auditory verbal hallucinations are related to cortical thinning in the left middle temporal gyrus of patients with schizophrenia.
    Psychol Med. 2017 Jun 19:1-8. doi: 10.1017/S0033291717001520.
    PubMed     Text format     Abstract available


  203. BORA E, Ozerdem A
    Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia.
    Psychol Med. 2017 Jun 6:1-14. doi: 10.1017/S0033291717001490.
    PubMed     Text format     Abstract available


    May 2017
  204. WALTON E, Hibar DP, van Erp TGM, Potkin SG, et al
    Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium.
    Psychol Med. 2017 May 26:1-13. doi: 10.1017/S0033291717001283.
    PubMed     Text format     Abstract available


  205. ZHENG W, Li XH, Yang XH, Cai DB, et al
    Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Psychol Med. 2017 May 22:1-10. doi: 10.1017/S0033291717001271.
    PubMed     Text format     Abstract available


  206. DI BIASE MA, Cropley VL, Baune BT, Olver J, et al
    White matter connectivity disruptions in early and chronic schizophrenia.
    Psychol Med. 2017 May 22:1-14. doi: 10.1017/S0033291717001313.
    PubMed     Text format     Abstract available


  207. MORITZ S, Klein JP, Desler T, Lill H, et al
    Neurocognitive deficits in schizophrenia. Are we making mountains out of molehills?
    Psychol Med. 2017 May 9:1-11. doi: 10.1017/S0033291717000939.
    PubMed     Text format     Abstract available


  208. BORA E, Binnur Akdede B, Alptekin K
    Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis.
    Psychol Med. 2017 May 4:1-14. doi: 10.1017/S0033291717000952.
    PubMed     Text format     Abstract available


  209. KRAKAUER K, Ebdrup BH, Glenthoj BY, Raghava JM, et al
    Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms.
    Psychol Med. 2017 May 3:1-19. doi: 10.1017/S0033291717001210.
    PubMed     Text format     Abstract available


  210. ALDERSON HL, Semple DM, Blayney C, Queirazza F, et al
    Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study.
    Psychol Med. 2017 May 3:1-8. doi: 10.1017/S0033291717001118.
    PubMed     Text format     Abstract available


  211. LEES J, Michalopoulou PG, Lewis SW, Preston S, et al
    Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial.
    Psychol Med. 2017 May 3:1-11. doi: 10.1017/S0033291717000885.
    PubMed     Text format     Abstract available


    April 2017
  212. ORANJE B, Aggernaes B, Rasmussen H, Ebdrup BH, et al
    Selective attention and mismatch negativity in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy.
    Psychol Med. 2017 Apr 26:1-11. doi: 10.1017/S0033291717000599.
    PubMed     Text format     Abstract available


  213. PAN YJ, Yeh LL, Chan HY, Chang CK, et al
    Transformation of excess mortality in people with schizophrenia and bipolar disorder in Taiwan.
    Psychol Med. 2017 Apr 26:1-11. doi: 10.1017/S0033291717001040.
    PubMed     Text format     Abstract available


  214. SPENCER BWJ, Shields G, Gergel T, Hotopf M, et al
    Diversity or disarray? A systematic review of decision-making capacity for treatment and research in schizophrenia and other non-affective psychoses.
    Psychol Med. 2017 Apr 26:1-17. doi: 10.1017/S0033291717000502.
    PubMed     Text format     Abstract available


  215. PARELLADA M, Pina-Camacho L, Moreno C, Aleman Y, et al
    Insular pathology in young people with high-functioning autism and first-episode psychosis.
    Psychol Med. 2017 Apr 24:1-11. doi: 10.1017/S0033291717000988.
    PubMed     Text format     Abstract available


  216. OUELLET-PLAMONDON C, Abdel-Baki A, Salvat E, Potvin S, et al
    Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes.
    Psychol Med. 2017 Apr 20:1-11. doi: 10.1017/S0033291717000976.
    PubMed     Text format     Abstract available


  217. VERMEULEN J, van Rooijen G, Doedens P, Numminen E, et al
    Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.
    Psychol Med. 2017 Apr 11:1-12. doi: 10.1017/S0033291717000873.
    PubMed     Text format     Abstract available


  218. DEMJAHA A, Lappin JM, Stahl D, Patel MX, et al
    Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors.
    Psychol Med. 2017 Apr 11:1-9. doi: 10.1017/S0033291717000435.
    PubMed     Text format     Abstract available


  219. KNAPP F, Viechtbauer W, Leonhart R, Nitschke K, et al
    Planning performance in schizophrenia patients: a meta-analysis of the influence of task difficulty and clinical and sociodemographic variables.
    Psychol Med. 2017 Apr 7:1-15. doi: 10.1017/S0033291717000459.
    PubMed     Text format     Abstract available


  220. CHIEN WT, Bressington D, Yip A, Karatzias T, et al
    An international multi-site, randomized controlled trial of a mindfulness-based psychoeducation group programme for people with schizophrenia.
    Psychol Med. 2017 Apr 4:1-16. doi: 10.1017/S0033291717000526.
    PubMed     Text format     Abstract available


    March 2017
  221. EMSLEY R, Asmal L, du Plessis S, Chiliza B, et al
    Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment.
    Psychol Med. 2017 Mar 28:1-10. doi: 10.1017/S0033291717000642.
    PubMed     Text format     Abstract available


  222. TEMPELAAR WM, Termorshuizen F, MacCabe JH, Boks MP, et al
    Educational achievement in psychiatric patients and their siblings: a register-based study in 30 000 individuals in The Netherlands.
    Psychol Med. 2017;47:776-784.
    PubMed     Text format     Abstract available


  223. AAS M, Kauppi K, Brandt CL, Tesli M, et al
    Childhood trauma is associated with increased brain responses to emotionally negative as compared with positive faces in patients with psychotic disorders.
    Psychol Med. 2017;47:669-679.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: